| Filed On | Filing |
|---|---|
| 13 Nov 2026 | S-3 |
| 12 Nov 2026 |
Form 4: Lee Gary K., Chief Scientific Officer
Sold 129 shares ($2.05K) |
| 12 Nov 2026 |
Form 4: Hill Stephen J., Chief Operating Officer
Sold 88 shares ($1.4K) |
| 12 Nov 2026 |
Form 4: Seely Lynn, Director
Sold 545 shares ($8.68K) |
| 12 Nov 2026 |
Form 4: Bulis Veronica Sanchez, VP, Corporate Controller
Sold 416 shares ($6.63K) |
| 10 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 |
Form 4: Arch Venture Partners IX, Llc, 10% owner and 4 others
Bought 2,321,262 shares ($25M) |
| 05 Nov 2026 |
Form 4: Arch Venture Fund XIII, L.p., 10% owner and 8 others
Bought 2,321,262 shares ($25M) |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., November 4, 2026 -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, to... |
| 04 Nov 2026 |
8-K: Unregistered Sales of Equity Securities
On November 3, 2026, Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to... |
| 13 Oct 2026 |
Form 4: Aguirre Jarrad Mattieu, Chief Medical Officer
Sold 422 shares ($3.64K) |
| 10 Sep 2026 |
Form 4: Shook David, Chief Medical Officer
Sold 500 shares ($6.35K) |
| 10 Sep 2026 |
Form 4: Aguirre Jarrad Mattieu, Chief Medical Officer
Granted 47,500 Option (right to buy) |
| 10 Sep 2026 |
Form 3: Aguirre Jarrad Mattieu, Chief Medical Officer
Holds 20,279 shares of Common Stock |
| 10 Sep 2026 |
8-K: Other Events
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer |
| 25 Aug 2026 |
Form 4: Seely Lynn, Director
Sold 9,589 shares ($149K) |
| 25 Aug 2026 |
Form 4: Hill Stephen J., Chief Operating Officer
Sold 989 shares ($15.4K) |
| 25 Aug 2026 |
Form 4: Lee Gary K., Chief Scientific Officer
Sold 1,457 shares ($22.6K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
Loading...